Ted Harding
Ufficiale delle Risorse Umane presso JOUNCE THERAPEUTICS, INC.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Kevin Tang | M | 57 | - | |
Jacquelyn Sandell | F | - | 5 anni | |
Eric Laub | M | - | 3 anni | |
Allison Nance | F | - | 8 anni | |
Michael Hearne | M | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 anni |
John Miller | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
Suzanne Fleming | F | 63 |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 2 anni |
Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
Norman Selby | M | 71 |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 3 anni |
Patrice Coissac | M | 75 | 8 anni | |
John Moriarty | M | 56 | 6 anni | |
Matthew DeLawder | M | - | 5 anni | |
Steve Weiss | M | 55 | 4 anni | |
Mittie Doyle | M | 59 | 3 anni | |
Mary Reumuth | F | 48 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
Julie Smith | F | 53 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 4 anni |
Saqib Islam | M | 54 | 3 anni | |
Rick Gyory | M | - |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 6 anni |
Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 anni |
Scott Requadt | M | 56 |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 3 anni |
Francis Wright | M | 76 | 2 anni | |
Adelene Perkins | F | 54 |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 8 anni |
Thomas Dubin | M | 62 | 12 anni | |
Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 anni |
Rebecca Velez Frey | F | - | 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 20 | 76.92% |
Canada | 7 | 26.92% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ted Harding
- Contatti personali